Striking a Balance between Carbonate/Carbamate Linkage Bond and Reduction-Sensitive Disulfide Bond-bearing Linker for Tailored Controlled Release: In Situ Covalently Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation.
Huicong Zhang,Kuanglei Wang,Kexin Na,Dan Li,Zhenbao Li,Dongyang Zhao,Lu Zhong,Menglin Wang,Longfa Kou,Cong Luo,Haotian Zhang,Qiming Kan,Huaiwei Ding,Zhonggui He,Jin Sun
DOI: https://doi.org/10.1021/acs.jmedchem.8b00293
IF: 8.039
2018-01-01
Journal of Medicinal Chemistry
Abstract:To address the challenges of rapid enzyme inactivation, poor tumor targeting, and acquired drug resistance in gemcitabine (GEM) application, we report two groups of maleimide-functionalized GEM prodrugs conjugating covalently in situ with Cys-34 of blood-circulating albumin and then resulting in macromolecular prodrugs after intravenous administration. Tailored and accurate controlled release was achieved through different combinations of linkage bonds, relatively stable and labile (carbamate and carbonate, respectively), and linkers with or without insertion of a disulfide bond. Interestingly, we found that the overall advantages or disadvantages brought by a disulfide bond varied with the stability of the linkage bond. Finally, the carbonate linkage bond-bearing group, especially the one with a linker lacking a disulfide bond, stood out with remarkably increased bioavailability (21-fold greater than GEM) and efficient tumor free-GEM accumulation (8-fold of GEM), which consequently contributed to excellent in vivo antitumor efficacy.